Jason Bednar
Stock Analyst at Piper Sandler
(2.26)
# 2,432
Out of 4,829 analysts
168
Total ratings
41%
Success rate
-5.8%
Average return
Main Sectors:
Stocks Rated by Jason Bednar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SOLV Solventum | Maintains: Neutral | $80 → $78 | $74.80 | +4.28% | 5 | May 9, 2025 | |
| KRMD KORU Medical Systems | Maintains: Neutral | $4.5 → $3.5 | $3.24 | +8.02% | 7 | May 8, 2025 | |
| MASI Masimo | Reiterates: Overweight | $215 → $200 | $163.56 | +22.28% | 15 | May 7, 2025 | |
| BDX Becton, Dickinson and Company | Downgrades: Neutral | $260 → $185 | $175.34 | +5.51% | 9 | May 2, 2025 | |
| LUNG Pulmonx | Reiterates: Overweight | $10 → $9 | $3.68 | +144.57% | 11 | May 1, 2025 | |
| ALGN Align Technology | Reiterates: Overweight | $235 → $250 | $189.00 | +32.28% | 30 | May 1, 2025 | |
| XRAY DENTSPLY SIRONA | Maintains: Neutral | $20 → $16 | $16.75 | -4.48% | 8 | Apr 30, 2025 | |
| HSIC Henry Schein | Maintains: Overweight | $83 → $77 | $70.47 | +9.27% | 7 | Apr 30, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $18 → $17 | $18.56 | -8.41% | 12 | Apr 30, 2025 | |
| SHC Sotera Health Company | Maintains: Neutral | $15 → $13 | $13.50 | -3.70% | 2 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $34 | $18.57 | +83.09% | 10 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $116 → $112 | $98.73 | +13.44% | 10 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4.5 | $2.15 | +109.79% | 3 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $120 → $115 | $84.45 | +36.18% | 12 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $260 → $265 | $233.10 | +13.69% | 9 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $6 | $1.83 | +227.87% | 5 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $2.80 | +150.00% | 5 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3.5 → $1 | $0.20 | +412.82% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $310 → $372 | $561.43 | -33.74% | 4 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $95 | $74.11 | +28.19% | 1 | Apr 19, 2023 |
Solventum
May 9, 2025
Maintains: Neutral
Price Target: $80 → $78
Current: $74.80
Upside: +4.28%
KORU Medical Systems
May 8, 2025
Maintains: Neutral
Price Target: $4.5 → $3.5
Current: $3.24
Upside: +8.02%
Masimo
May 7, 2025
Reiterates: Overweight
Price Target: $215 → $200
Current: $163.56
Upside: +22.28%
Becton, Dickinson and Company
May 2, 2025
Downgrades: Neutral
Price Target: $260 → $185
Current: $175.34
Upside: +5.51%
Pulmonx
May 1, 2025
Reiterates: Overweight
Price Target: $10 → $9
Current: $3.68
Upside: +144.57%
Align Technology
May 1, 2025
Reiterates: Overweight
Price Target: $235 → $250
Current: $189.00
Upside: +32.28%
DENTSPLY SIRONA
Apr 30, 2025
Maintains: Neutral
Price Target: $20 → $16
Current: $16.75
Upside: -4.48%
Henry Schein
Apr 30, 2025
Maintains: Overweight
Price Target: $83 → $77
Current: $70.47
Upside: +9.27%
Envista Holdings
Apr 30, 2025
Maintains: Neutral
Price Target: $18 → $17
Current: $18.56
Upside: -8.41%
Sotera Health Company
Apr 23, 2025
Maintains: Neutral
Price Target: $15 → $13
Current: $13.50
Upside: -3.70%
Apr 23, 2025
Maintains: Overweight
Price Target: $42 → $34
Current: $18.57
Upside: +83.09%
Apr 23, 2025
Maintains: Overweight
Price Target: $116 → $112
Current: $98.73
Upside: +13.44%
Mar 28, 2025
Maintains: Overweight
Price Target: $5 → $4.5
Current: $2.15
Upside: +109.79%
Mar 7, 2025
Reiterates: Overweight
Price Target: $120 → $115
Current: $84.45
Upside: +36.18%
Feb 3, 2025
Maintains: Overweight
Price Target: $260 → $265
Current: $233.10
Upside: +13.69%
Nov 7, 2024
Maintains: Overweight
Price Target: $8 → $6
Current: $1.83
Upside: +227.87%
Aug 15, 2024
Reiterates: Overweight
Price Target: $7
Current: $2.80
Upside: +150.00%
Aug 7, 2024
Maintains: Overweight
Price Target: $3.5 → $1
Current: $0.20
Upside: +412.82%
Jan 3, 2024
Maintains: Outperform
Price Target: $310 → $372
Current: $561.43
Upside: -33.74%
Apr 19, 2023
Initiates: Overweight
Price Target: $95
Current: $74.11
Upside: +28.19%